June 26, 2017 9:32 AM ET

Pharmaceuticals

Company Overview of PanOptica, Inc.

Company Overview

PanOptica, Inc., a biopharmaceutical company, is engaged in licensing and developing a portfolio of exciting and innovative therapeutics for major ophthalmic disease. The company offers PAN-90806, a small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy. It serves pharmaceutical companies. The company was founded in 2009 and is based in Bernardsville, New Jersey.

150 Morristown Road

Suite 205

Bernardsville, NJ 07924-2626

United States

Founded in 2009

Phone:

908-766-2202

Fax:

908-766-2121

Key Executives for PanOptica, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 58
Co-founder, Chief Medical Officer and Executive Vice-President
Executive Director of Finance and Controller
Senior Director of Clinical Development
Executive Director of Clinical Operations
Compensation as of Fiscal Year 2016.

PanOptica, Inc. Key Developments

PanOptica, Inc. Reports Positive Results from Phase 1/2 Clinical Trial of PAN-90806, a Novel Topical Anti-VEGF Eye Drop

PanOptica, Inc. reported positive data from a Phase 1/2 study of PAN-90806, a topical anti-vascular endothelial growth factor (anti-VEGF) eye drop in development for the treatment of neovascular eye diseases. Based on these results, the company plans to initiate a Phase 1/2 clinical trial of a next-generation formulation of topical PAN-90806 in patients with neovascular age-related macular degeneration (wet AMD) in 2017. PAN-90806 also is being studied in a Phase 1 trial of patients with Proliferative Diabetic Retinopathy, and may have utility in other chronic neovascular eye diseases, including retinal vein occlusion, and other VEGF-dependent neovascular eye diseases. Retina specialists also have expressed interest in studying PAN-90806 as a potential strategy for preventing the progression to wet AMD in patients with high-risk dry AMD. PAN-90806 is a potent and selective inhibitor of VEGF receptor signaling. VEGF is a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two pathological processes that contribute to the vision loss associated with wet AMD. In pre-clinical research using validated ocular angiogenesis models, topically administered PAN-90806 suppressed the formation of new blood vessels. In non-clinical pharmacokinetic studies, topical administration of PAN-90806 achieved significant and sustained levels in the retina and choroid of multiple species, supporting further investigation of PAN-90806.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PanOptica, Inc., please visit panopticapharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.